Sino Biological's launch of SwiftFluo® TR-FRET Kits pioneers a new era in high- throughput kinase inhibitor screening

Sino Biological, Inc. is proud to announce the launch of its innovative SwiftFluo® TR-FRET Kinase Assay Kits, a ready-to-use, high-performance solution designed to accelerate kinase activity detection and high-throughput kinase inhibitor screening.

Leveraging advanced Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) technology, these kits deliver exceptional sensitivity, low background, and robust reproducibility. This enables rapid, reliable, and scalable screening of kinase inhibitors, outperforming traditional methods such as radioactive assays, ELISA, and fluorescence intensity-based techniques.

Optimized for profiling more than 60 tyrosine kinases (TKs), 150 serine/threonine kinases (STKs), and 15 cyclin-dependent kinases (CDKs), these SwiftFluo® TR-FRET kits provide broad coverage across key signaling pathways. In addition to kits, Sino Biological offers related substrates and all corresponding biologically active kinases as standalone products, providing maximum flexibility for custom assay design.

Researchers can perform homogeneous, no-wash assays in a simple add-and-read format compatible with standard HTS platforms, eliminating assay development time and streamlining workflows.” 

Dr. Rob Burgess, Chief Business Officer, Sino Biological US, Inc.

We are excited to introduce SwiftFluo® TR-FRET kits as a powerful tool for the global research community,” said Dr. Jie Zhang, Sino Biological’s General Manager. “These kits are thoughtfully designed to balance ease of use, cost efficiency, and reproducible data, which are critical requirements for successful high-throughput screening campaigns.”

Researchers can visit www.sinobiological.com or download the technical Q&A handbook to explore how SwiftFluo® TR-FRET kits accelerate kinase drug discovery.

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Sino Biological Inc.. (2026, January 21). Sino Biological's launch of SwiftFluo® TR-FRET Kits pioneers a new era in high- throughput kinase inhibitor screening. News-Medical. Retrieved on January 21, 2026 from https://www.appetitewellbeing.com/news/20260121/Sino-Biologicals-launch-of-SwiftFluoc2ae-TR-FRET-Kits-pioneers-a-new-era-in-high-throughput-kinase-inhibitor-screening.aspx.

  • MLA

    Sino Biological Inc.. "Sino Biological's launch of SwiftFluo® TR-FRET Kits pioneers a new era in high- throughput kinase inhibitor screening". News-Medical. 21 January 2026. <https://www.appetitewellbeing.com/news/20260121/Sino-Biologicals-launch-of-SwiftFluoc2ae-TR-FRET-Kits-pioneers-a-new-era-in-high-throughput-kinase-inhibitor-screening.aspx>.

  • Chicago

    Sino Biological Inc.. "Sino Biological's launch of SwiftFluo® TR-FRET Kits pioneers a new era in high- throughput kinase inhibitor screening". News-Medical. https://www.appetitewellbeing.com/news/20260121/Sino-Biologicals-launch-of-SwiftFluoc2ae-TR-FRET-Kits-pioneers-a-new-era-in-high-throughput-kinase-inhibitor-screening.aspx. (accessed January 21, 2026).

  • Harvard

    Sino Biological Inc.. 2026. Sino Biological's launch of SwiftFluo® TR-FRET Kits pioneers a new era in high- throughput kinase inhibitor screening. News-Medical, viewed 21 January 2026, https://www.appetitewellbeing.com/news/20260121/Sino-Biologicals-launch-of-SwiftFluoc2ae-TR-FRET-Kits-pioneers-a-new-era-in-high-throughput-kinase-inhibitor-screening.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
FDA approved PDE4 inhibitor roflumilast for atopic dermatitis